Dallas, TX -- (SBWIRE) -- 07/06/2015 -- According to WHO, depression, an affective mental disorder, is quite common with an incidence of 3-5%. Currently, the number of depression patients has exceeded 90 million in China and still keeps increasing. It is expected that by 2020, depression will become the second biggest threat to human health.
As a drug of the selective serotonin reuptake inhibitor (SSRI) type, paroxetine is mainly used for the treatment of depression, obsessive-compulsive disorder and social anxiety and is among one of the three SSRI drugs with certain efficacy (the other two being fluoxetine and paroxetine)
Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=394393
Paroxetine develops fast after entering China despite a slight decline in 2014, annual sales value rising from less than CNY 60 million in 2005 to CNY 204 million in 2013 and CAGR during this period reaching up to 17.3%. Sino-American Tianjin Smith Kline & French Laboratories Ltd, GlaxoSmithKline plc (CA), Beijing Wansheng Pharmaceutical Co., Ltd, Zhejiang Huahai Pharmaceutical Co., Ltd and Zhejiang Jianfeng Pharmaceutical Holdings occupy the majority of the Chinese market, among which Sino-American Tianjin Smith Kline & French Laboratories Ltd had the largest market share of about 69% for sales value in 2014.
With the increased mental pressure brought about by economic development and lifestyle change, the number of depression patients keeps growing too. Therefore, the market size of paroxetine is expected to expand in the next few years in China.
Readers can get at least the following information from this report:
-market size of paroxetine in China
-competitive landscape of paroxetine in Chinese market
-price of paroxetine made by different enterprises in China
-market outlook of paroxetine in China
-the author suggests the following groups of people purchase this report:
-manufacturers of antidepressant
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service
Complete report is available at
http://www.rnrmarketresearch.com/investigation-report-on-china-paroxetine-market-2010-2019-market-report.html
Table of Contents
1 Related Concepts of Paroxetine
1.1 Indication
1.2 Sales Status in Global Market
2 Market Profile of Paroxetine in China
2.1 Patent and Approval Status of Paroxetine in China
2.2 Major Manufacturers
2.3 Market Size
3 Survey on Sales Status of Paroxetine in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 Survey o Market Share of Major Manufacturers of Paroxetine in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 Survey on Dosage Forms of Paroxetine in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 Reference Price of Paroxetine in Chinese Hospitals in 2014
6.1 Sino-American Tianjin Smith Kline & French Laboratories Ltd (Trade Name: Seroxat)
6.2 GlaxoSmithKline plc (Canada) (Trade Name: Seroxat)
6.3 Beijing Wansheng Pharmaceutical Co., Ltd
6.4 Zhejiang Huahai Pharmaceutical Co., Ltd (Trade Name: LEYOU)
6.5 Zhejiang Jianfeng Pharmaceutical Holdings (Trade Name: Shutanluo)
7 Major Manufacturers of Paroxetine in Chinese Market, 2010-2014
7.1 Sino-American Tianjin Smith Kline & French Laboratories Ltd
7.2 Beijing Wansheng Pharmaceutical Co., Ltd
7.3 Zhejiang Huahai Pharmaceutical Co., Ltd
7.4 Zhejiang Jianfeng Pharmaceutical Holdings
7.5 GlaxoSmithKline plc (CA)
8 Market Outlook of Paroxetine in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape